نتایج جستجو برای: fabry disease

تعداد نتایج: 1493456  

Journal: :Lancet 2005
Arndt Rolfs Tobias Böttcher Marlies Zschiesche Peter Morris Bryan Winchester Peter Bauer Uwe Walter Eilhard Mix Mathias Löhr Klaus Harzer Ulf Strauss Jens Pahnke Annette Grossmann Reiner Benecke

BACKGROUND Strokes are an important cause of morbidity and mortality in young adults. However, in most cases the cause of the stroke remains unclear. Anderson-Fabry disease is an X-linked recessive lysosomal storage disease resulting from deficient alpha-galactosidase and causes an endothelial vasculopathy followed by cerebral ischaemia. To determine the importance of Fabry disease in young peo...

Journal: :Current Pharmaceutical Design 2013

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2010
Alberto Ortiz Bruno Cianciaruso Marta Cizmarik Dominique P Germain Renzo Mignani João Paulo Oliveira Jacobo Villalobos Bojan Vujkovac Stephen Waldek Christoph Wanner David G Warnock

BACKGROUND Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase activity, is associated with progressive loss of kidney function. This study was undertaken to characterize Fabry disease among patients who reached end-stage renal disease. METHODS Data from 2,712 patients in the Fabry Registry were analysed to identify clinical characteristics of pat...

Journal: :Polish Archives of Internal Medicine 2018

Journal: :Journal of Rare Cardiovascular Diseases 2012

Journal: :Jornal Brasileiro de Nefrologia 2016

2017
Michael Mauer Alexey Sokolovskiy Jay A Barth Jeffrey P Castelli Hadis N Williams Elfrida R Benjamin Behzad Najafian

OBJECTIVE Deficiency of α-galactosidase A (αGal-A) in Fabry disease leads to the accumulation mainly of globotriaosylceramide (GL3) in multiple renal cell types. Glomerular podocytes are relatively resistant to clearance of GL3 inclusions by enzyme replacement therapy (ERT). Migalastat, an orally bioavailable small molecule capable of chaperoning misfolded αGal-A to lysosomes, is approved in th...

Journal: :Journal of the American Society of Nephrology : JASN 2007
Hindia Tahir Leslie L Jackson David G Warnock

This report describes an open-label, nonrandomized, prospective evaluation of the effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy on patients who have Fabry disease and also received enzyme replacement therapy with agalsidase-beta, given at 1 mg/kg body wt every 2 wk. Previous placebo-controlled phase III and phase IV trials with agalsidase-beta demon...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید